Different measures of fitness and physical activity were inversely associated with future CVD events and all-cause death, also in individuals with a high genetic CVD predisposition.
In a large prospective study, risk of all-cause mortality increases above 100 g alcohol per week, and positive associations with alcohol intake were seen mostly for stroke and HF, as opposed to MI.
In the AXAFA-AFNET 5 trial, continuous apixaban therapy was non-inferior to continuous VKA treatment in terms of stroke, bleedings, cognitive function and MRI-detected acute brain lesions.
Visit-to-visit variability in fasting measurements of HDL-c, TG, and LDL-c is predictive of coronary events, CV events, and TG and LDL-c variability is also predictive of incident diabetes.
Neither FH mutations, nor high LDL-c levels were associated with an increased risk of ischemic stroke, with the exception of patients with a history of ischemic heart disease.
Incident atrial fibrillation (AF) is associated with both greater cognitive decline and increased risk of dementia compared with individuals without AF, independent of clinical ischemic stroke.
Mendelian randomization study suggests that lowering LDL affects large artery atherosclerosis, but not small artery occlusion or cardioembolic stroke, while increasing HDL may benefit small artery disease.
Following the results from the FOURIER trial, EMA’s CHMP has issued a positive opinion for the PCSK9 inhibitor evolocumab to reduce CV risk in patients with established ASCVD.
New data of the ongoing GLORIA-AF registry on use of dabigatran in AF show low rates of major bleeding and stroke, and long-term safety data are consistent with other real-world and RCT evidence.
ACC 2018 Treatment with canakinumab reduced MACE+ in patients with CKD in the CANTOS trial, with a stronger reduction in those who achieved on-treatment hsCRP<2 mg/mL compared to >2 mg/mL.
ACC 2018 In the digital mSToPS trial using patient-generated data, a wearable ECG patch improved the rate of AF diagnosis at 1 year compared to routine care.
Overweight and obese individuals have a significantly increased long-term risk for CVD morbidity, and a similar or shorter total longevity, compared with individuals with a normal BMI.